84
Participants
Start Date
July 24, 2014
Primary Completion Date
April 30, 2018
Study Completion Date
April 30, 2018
BGJ398
BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
University of Pittsburgh Cancer Institute Hillman Cancer Center (2), Pittsburgh
Lehigh Valley Health Network, Allentown
Cancer Treatment Centers of America Eastern Regional Medical Center, Philadelphia
St. Agnes Hospital St. Agnes Hospital (2), Baltimore
Virginia Cancer Specialists Fairfax Northern Virginia, Fairfax
Shenandoah Oncology Shenandoah Oncology (5), Winchester
Wake Forest Baptist Health Hem & Onc Medical Center, Winston-Salem
Waverly Hematology Oncology, Cary
Duke University Medical Center Seeley G. Mudd Bldg., Durham
NorthWest Georgia Oncology Centers NW Georgia Oncology, Marietta
Harbin Clinic Medical Oncology Clin. Res., Rome
University of Miami Sylvester Comprehensive Cancer, Miami
Florida Cancer Specialists Florida Cancer Specialists 36, Fort Myers
Alabama Oncology St. Vincent's Birmingham, Birmingham
Tennessee Oncology Tennessee Oncology (3), Nashville
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga
University of Louisville / James Graham Brown Cancer Center SC, Louisville
University Hospitals of Cleveland Seidman Cancer Center University Hospitals, Cleveland
Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Oncology Hematology Care Inc Oncology Hematology Care 2, Cincinnati
Community Clinical Research Center, Anderson
Indiana University Indiana Univ. - Purdue Univ., Indianapolis
Northern Indiana Cancer Research Consortium No. Indiana Cancer Res., South Bend
Cancer and Hematology Centers of West Michigan Dept. of Oncology, Grand Rapids
Minnesota Oncology Hematology, P.A. Minnesota Oncology Hem (27), Minneapolis
Sanford University of South Dakota Medical Center Sanford Health, Sioux Falls
Sanford Hematology Oncology, Fargo
Billings Clinic Billings Clinic (8), Billings
Illinois Cancer Specialists, Arlington Heights
Lurie Children's Hospital of Chicago Developmental Therapeutics, Chicago
Research Medical Center Research Med Center (2), Kansas City
The Center for Cancer and Blood Disorders, Fort Worth
Texas Oncology Cancer Care & Research Center Texas Oncology, Waco
Oncology Consultants Oncology Group, Houston
Houston Methodist Cancer Center, Houston
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3), Houston
Deke Slayton Cancer Center Deke Slayton Cancer Center (2), Webster
Cancer Therapy & Research Center UT Health Science Center Oncology Dept., San Antonio
Texas Oncology, McAllen
Rocky Mountain Cancer Centers Rocky Mountain Cancer Ctr (50), Greenwood Village
University of Utah / Huntsman Cancer Institute SC-2, Salt Lake City
Utah Cancer Specialists Utah Cancer Specialists (11), Salt Lake City
Intermountain Medical Center Intermountain Healthcare, Murray
Northern Utah Cancer Associates Northern Utah Assoc (3), Ogden
New Mexico Cancer Center, Albuquerque
North County Oncology Medical Clinic Inc, Oceanside
San Francisco General Hospital San Francisco Gen Hosp (7), San Francisco
Northwest Cancer Specialists Northwest Cancer, Portland
Bend Memorial Clinic Bend Mem. Clinic, Bend
Northwest Medical Specialties NW Medical Specialties, Tacoma
Norwalk Hospital, Norwalk
Southcoast Centers for Cancer Care, Fairhaven
Dartmouth Hitchcock Medical Center Dartmouth Hitchcock - Lebanon, Bedford
Rutgers Cancer Institute of New Jersey, New Brunswick
University of N C at Chapel Hill Physician Office Building, Chapel Hill
Rhode Island Hospital Rhode Island Hosp. (2), Providence
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY